Biotechnology company Moderna, Inc. (MRNA) reported Friday a net loss of $1.12 billion or $2.91 per share for the fourth quarter, compared to net income of $217 million or $3.0.55 per share in the prior-year quarter.
On average, 14 analysts polled expected the company to report a loss of $2.76 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the quarter slumped to $966 million from last year's $2.81 billion in the same quarter last year. Analysts expected revenues of $941.14 million for the quarter.
Looking ahead to fiscal 2025, the company continues to project revenues between $1.5 billion and $2.5 billion. The Street is looking for revenues of $2.22 billion for the year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.